Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1268-1274

  Squarcione, S ^a   Sgricia, S ^b   Biasio, L R ^c   Perinetti, E ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Servizio di Vaccinazioni   (Italy)

^c Pasteur Merieux MSD SpA   (Italy)

Author keywords

Elderly; Immunogenicity; Influenza; Reactogenicity; Vaccination

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS ANTIBODY;

ABSCESS; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION; HUMAN; HYPERHIDROSIS; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; OPEN STUDY; PAIN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN INDURATION; VIRION; VIRUS IMMUNITY; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; ITALY; MALE; PAIN; SAFETY; VACCINATION; VACCINES; VACCINES, COMBINED; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 0037424108     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00401-2     Document Type: Article

References (32)

1. Wiselka M. Influenza: diagnosis, management, and prophylaxis. Br. Med. J. 308:1994;1341-1345.
2. Nicholson K.G. Influenza vaccination and the elderly. Br. Med. J. 301:1990;617-618.
3. Bradley S.F. Influenza in the elderly. Prevention is the best strategy in high-risk populations. Postgrad. Med. 99:1996;138-149.
4. LaForce F.M., Nichol K.L., Cox N.J. Influenza: virology, epidemiology, disease, and prevention. Am. J. Prev. Med. 10(Suppl.):1994;31-44.
5. Margolis K.L., Poland G.A., Nichol K.L.et al. Frequency of adverse reactions after influenza vaccination. Am. J. Med. 88:1990;27-30.
6. Margolis K.L., Nichol K.L., Poland G.A., Pluhar R.E. Frequency of adverse reactions to influenza vaccine in the elderly - a randomized, placebo-controlled trial. J. Am. Med. Assoc. 264:1990;1139-1141.
7. Nichol K.L., Margolis K.L., Wuorenma J.et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 22:1994;778-784.
8. Carrat F., Valleron A.J. Le vaccin antigrippal. Revue bibliographique. Rev. Mal. Resp. 11:1994;239-255.
9. Govaert Th.M.E., Thijs C.T., Masurel N.et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. J. Am. Med. Assoc. 272:1994;1661-1665.
10. Baldo V., Menegon T., Buoro S.et al. Anti-influenza vaccination in elderly subjects: experience with adjuvanted vaccines. Ann. Ig. 11:1999;369-374. [in Italian].
11. Dooley M., Goa K.L. Adjuvanted influenza vaccine. BioDrugs. 14:2000;61-69.
12. Barchfeld G.L., Hessler A.L., Chen M. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine. 17:1999;695-704.
13. Minutello M., Senatore F., Cecchinelli G.et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 17:1999;99-104.
14. De Donato S., Granoff D., Minutello M.et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine. 17:1999;3094-3101.
15. Menegon T., Baldo V., Bonello C., Dalla Costa D., Di Tommaso A., Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol. 15:1999;573-576.
16. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 19:2001;2673-2680.
17. Odelin M.F., Pozzetto B., Aymard M.et al. Role of influenza vaccination in the elderly during an epidemic of A/H1N1 virus in 1988-1989: clinical and serological data. Gerontology. 39:1993;109-116.
18. Zei T., Neri M., Iorio A.M.et al. Immunogenicity of trivalent subunit and split influenza vaccines (1989-1990 winter season) in volunteers of different groups of age. Vaccine. 9:1991;613-617.
19. Gasparini R., Nante N., Miotti P.G.et al. Sperimentazione di un vaccino anti-influenzale "split" in soggetti anziani ed in adulti sani. Giorn. Ig Med. Prev. 27:1986;137-146.
20. Capasso A.D., Marra F., Narni Mancinelli F. Vaccinazione antinfluenzale di una popolazione di bambini "umprimed" Rass. Int. Clin. Ter. 70:1990;700-702.
21. De Dominicis R., Faggioli A., Toschi A.et al. Studio sperimentale sulla reattogenicità del vaccino anti-influenzale del tipo "split" Gli Ospedali della Vita. 1:1989;24-31.
22. Raschetti R, Rota MC, Salmaso, et al. SVEVA. Studio per la valutazione degli effetti collaterali della vaccinazione antinfluenzale. Rapporti ISTISAN 1997;5(Suppl):1-41.
23. Ott G, Barchfeld GL, Chernoff R, Radhakrishnan R, Van Hoogevest P, Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit approach.
24. Beyer W.E.P., Palache A.M., Baljet M.et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine. 7:1989;385-394.
25. Beyer W.E.P., Palache A.M., Sprenger M.J.W.et al. Effect of repeated annual influenza vaccination on vaccine seroresponse in young and elderly adults. Vaccine. 14:1996;1331-1339.
26. Govaert T.M.E., Sprenger M.J.W., Dinant G.J.et al. Immune response to influenza vaccination of elderly people. A randomised double-blind, placebo-controlled trial. Vaccine. 12:1994;1185-1189.
27. McElhaney J.E., Meneilly G.S., Lechelt K.E.et al. Split-influenza vaccines: do they provide adequate immunity in the elderly? J. Gerontol. Med. Sci. 29:1994;37-43.
28. Powers D.C. Influenza vaccination strategies for the elderly. Aging Immunol. Infect. Dis. 5:1996;47-54.
29. Aventis Pasteur. Clinical report on immunogenicty and safety of the inactivated influenza vaccine (split virion) 1998-1999 formulation - A 146 IVB1/GRT 09298. Data on file.
30. Palmer DF, Dowle WR, Coleman MT, Schild GC. Advanced laboratory technicals for immunological diagnostic. US Department of Health Education and Welfare, P.H.S. Atlanta, Immunology Series No. 6. Procedural guide. Part 2. Haemagglutination-inhibition test. 1975. p. 25-62.
31. Dowdle WR, Kendal AP, Noble GR. Influenza Viruses. In: Diagnostic procedures for viral, rickettsial and chlamydial infections. Washington (DC): American Public Health Association; 1979. p. 585-609.
32. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96).